310 related articles for article (PubMed ID: 29402301)
1. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
[TBL] [Abstract][Full Text] [Related]
2. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Park JJ; Yi JY; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
Biochem Pharmacol; 2012 Apr; 83(7):849-57. PubMed ID: 22266356
[TBL] [Abstract][Full Text] [Related]
3. ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor.
Holdbrooks AT; Britain CM; Bellis SL
J Biol Chem; 2018 Feb; 293(5):1610-1622. PubMed ID: 29233887
[TBL] [Abstract][Full Text] [Related]
4. ST6Gal-I-mediated sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances invasion.
Rao TC; Beggs RR; Ankenbauer KE; Hwang J; Ma VP; Salaita K; Bellis SL; Mattheyses AL
J Biol Chem; 2022 Apr; 298(4):101726. PubMed ID: 35157848
[TBL] [Abstract][Full Text] [Related]
5. Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells.
Britain CM; Bhalerao N; Silva AD; Chakraborty A; Buchsbaum DJ; Crowley MR; Crossman DK; Edwards YJK; Bellis SL
J Biol Chem; 2021; 296():100034. PubMed ID: 33148698
[TBL] [Abstract][Full Text] [Related]
6. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
[TBL] [Abstract][Full Text] [Related]
7. Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics.
Ankenbauer KE; Rao TC; Mattheyses AL; Bellis SL
J Biol Chem; 2023 Oct; 299(10):105217. PubMed ID: 37660914
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
Yang L; Li J; Ran L; Pan F; Zhao X; Ding Z; Chen Y; Peng Q; Liang H
J Gastrointest Surg; 2011 Jun; 15(6):942-57. PubMed ID: 21479670
[TBL] [Abstract][Full Text] [Related]
9. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
10. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.
Dorsett KA; Jones RB; Ankenbauer KE; Hjelmeland AB; Bellis SL
J Ovarian Res; 2019 Oct; 12(1):93. PubMed ID: 31610800
[TBL] [Abstract][Full Text] [Related]
11. Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.
Frasca F; Vella V; Nicolosi ML; Messina RL; Gianì F; Lotta S; Vigneri P; Regalbuto C; Vigneri R
J Clin Endocrinol Metab; 2013 Jun; 98(6):2502-12. PubMed ID: 23559083
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
13. DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Zhu S; Belkhiri A; El-Rifai W
Gastroenterology; 2011 Nov; 141(5):1738-48.e1-2. PubMed ID: 21741919
[TBL] [Abstract][Full Text] [Related]
14. The Glycosyltransferase ST6Gal-I Protects Tumor Cells against Serum Growth Factor Withdrawal by Enhancing Survival Signaling and Proliferative Potential.
Britain CM; Dorsett KA; Bellis SL
J Biol Chem; 2017 Mar; 292(11):4663-4673. PubMed ID: 28154177
[TBL] [Abstract][Full Text] [Related]
15. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells.
Swindall AF; Bellis SL
J Biol Chem; 2011 Jul; 286(26):22982-90. PubMed ID: 21550977
[TBL] [Abstract][Full Text] [Related]
16. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
[TBL] [Abstract][Full Text] [Related]
17. EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
Jo U; Park KH; Whang YM; Sung JS; Won NH; Park JK; Kim YH
Oncotarget; 2014 Mar; 5(5):1265-78. PubMed ID: 24658031
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
Meco D; Servidei T; Riccardi A; Ferlini C; Cusano G; Zannoni GF; Giangaspero F; Riccardi R
Neuro Oncol; 2009 Jun; 11(3):250-9. PubMed ID: 19033425
[TBL] [Abstract][Full Text] [Related]
19. The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling.
Jones RB; Dorsett KA; Hjelmeland AB; Bellis SL
J Biol Chem; 2018 Apr; 293(15):5659-5667. PubMed ID: 29475939
[TBL] [Abstract][Full Text] [Related]
20. Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance.
Ou L; He X; Liu N; Song Y; Li J; Gao L; Huang X; Deng Z; Wang X; Lin S
Mol Med Rep; 2020 Mar; 21(3):1449-1460. PubMed ID: 32016470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
